1. Home
  2. FHTX vs ETHM Comparison

FHTX vs ETHM Comparison

Compare FHTX & ETHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$5.34

Market Cap

247.1M

Sector

Health Care

ML Signal

HOLD

Logo Dynamix Corporation Class A Ordinary Shares

ETHM

Dynamix Corporation Class A Ordinary Shares

N/A

Current Price

$10.31

Market Cap

227.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FHTX
ETHM
Founded
2015
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
247.1M
227.0M
IPO Year
2020
2024

Fundamental Metrics

Financial Performance
Metric
FHTX
ETHM
Price
$5.34
$10.31
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$11.43
N/A
AVG Volume (30 Days)
158.3K
203.5K
Earning Date
11-05-2025
02-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,518,000.00
N/A
Revenue This Year
$40.89
N/A
Revenue Next Year
$11.89
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.95
$9.78
52 Week High
$6.79
$15.24

Technical Indicators

Market Signals
Indicator
FHTX
ETHM
Relative Strength Index (RSI) 59.84 N/A
Support Level $5.01 N/A
Resistance Level $5.95 N/A
Average True Range (ATR) 0.34 0.00
MACD 0.04 0.00
Stochastic Oscillator 66.10 0.00

Price Performance

Historical Comparison
FHTX
ETHM

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

About ETHM Dynamix Corporation Class A Ordinary Shares

Dynamix Corp is a blank check company.

Share on Social Networks: